Workflow
USANA Health Sciences(USNA)
icon
Search documents
USANA Health Sciences(USNA) - 2025 Q2 - Earnings Call Transcript
2025-07-23 16:02
Financial Data and Key Metrics Changes - Consolidated net sales grew 11% year over year and adjusted earnings per share increased 36% from the prior year [5] - The company ended the quarter debt-free with $151 million in cash on the balance sheet after repaying its line of credit [5] Business Line Data and Key Metrics Changes - The direct-to-consumer business, HYA, showed strong year-over-year top line growth with improved profitability [10] - RiseBar, acquired in 2022, delivered strong double-digit top line growth driven by solid order activity with key retail partners [11] Market Data and Key Metrics Changes - Sales in China outperformed expectations despite a drop in active customers, attributed partly to tariff activity and increased buy-up from consumers [15][16] - The company is optimistic about the long-term potential of the Chinese market despite economic uncertainties [17] Company Strategy and Development Direction - The company is implementing strategic initiatives to strengthen partnerships with brand partners, accelerate product innovation, and evolve brand messaging [6][8] - A new compensation plan is being introduced to modernize and simplify the direct sales model, aimed at attracting new generations of entrepreneurs [8][22] - The company plans to host more in-person events and launch several new products at the upcoming global convention [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth outlook for fiscal year 2025, believing that successful execution of strategies will deliver sustainable long-term growth [12][13] - The company is closely monitoring economic uncertainties and tariff impacts but has not seen significant negative effects thus far [23][24] Other Important Information - The company is investing significantly in the third quarter for the global convention and new product launches, which may create short-term pressure on operating margins [12] - The integration of acquired businesses is progressing well, with expectations for synergies and operational efficiencies to be realized in the coming quarters [30][33] Q&A Session Summary Question: Insights on sales performance in China - The performance in China was strong despite a drop in active customers, with tariff activity contributing to increased consumer buy-up [15][16] Question: Active customer count decline - The decline in active customer count was partly due to upcoming changes in the compensation program, which created some reservations among brand partners [18] Question: New brand partner compensation details - The new compensation program allows new brand partners to earn income more quickly, addressing challenges in early success [20][22] Question: Impact of tariffs on overall business - The impact of tariffs has been minimal, with proactive measures taken by the operations and procurement team [23][24] Question: Growth comparison for Chaya's second quarter sales - Chaya experienced significant growth compared to the previous year, with expectations for continued growth as new products are launched [28] Question: Integration synergies and operational efficiencies - The integration of Hyatt is progressing, with expectations for operational efficiencies to be realized in the future [30][33] Question: Share buyback strategy - The company will be opportunistic regarding share buybacks, discussing capital allocation at board meetings [35] Question: Outlook for additional acquisition opportunities - The company has an active M&A department looking for opportunities but will need time to build cash for appealing acquisitions [36]
USANA Health Sciences(USNA) - 2025 Q2 - Earnings Call Transcript
2025-07-23 16:00
Financial Data and Key Metrics Changes - Consolidated net sales grew 11% year over year and adjusted earnings per share increased 36% from the prior year [5] - The company ended the quarter debt-free with $151 million in cash on the balance sheet after repaying its line of credit [5] Business Line Data and Key Metrics Changes - The direct-to-consumer business, HYA, showed strong year-over-year top line growth with improved profitability [10] - RiseBar, acquired in 2022, delivered strong double-digit top line growth driven by solid order activity with key retail partners [11] Market Data and Key Metrics Changes - Sales in China outperformed expectations despite a drop in active customers, attributed to tariff activity and increased consumer buying [16][17] - The overall active customer count saw a decline, partially due to upcoming changes in the compensation programs [19] Company Strategy and Development Direction - The company is implementing strategic initiatives to strengthen partnerships with brand partners, accelerate product innovation, and evolve brand messaging [6][7] - A new compensation plan is being introduced to modernize and simplify the direct sales model, aimed at attracting new generations of entrepreneurs [8][22] - The company is focused on enhancing its product offerings and expanding its market reach through acquired businesses [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term potential of the Chinese market despite current economic uncertainties [18] - The company remains confident in its fiscal 2025 outlook and believes successful execution of strategies will deliver sustainable long-term growth [12] Other Important Information - The company plans to host a global convention to recognize brand partners and provide actionable training [10] - Investments in the third quarter are expected to create short-term pressure on operating margins due to the global convention and new product launches [12] Q&A Session Summary Question: Insights on sales performance in China - Management noted strong performance in China despite tariff activity, with optimism about long-term potential [16][17] Question: Active customer count decline - The decline was partially attributed to upcoming changes in the compensation program, with expectations for recovery in the third quarter [19] Question: New brand partner compensation details - Adjustments were made to allow new brand partners to earn income earlier in their journey, enhancing the incentive program [21][22] Question: Impact of tariffs on business - The impact of tariffs has been minimal, with proactive measures taken by the operations team [23][24] Question: Growth comparison for Chaya - Chaya experienced significant growth compared to the previous year, with expectations for continued growth in the coming months [25][27] Question: Integration synergies and operational efficiencies - Management is optimistic about operational initiatives and synergies from the integration of Hyatt, with progress expected in the coming quarters [28][30] Question: Future acquisition opportunities - The company has an active M&A department looking for opportunities, but it will take time to build sufficient cash for new acquisitions [33] Question: Competitive advantage from health initiatives - The company is well-positioned to respond to health trends, particularly in children's health through the acquisition of Hyatt [40][43] Question: Tools and infrastructure for brand partners - Enhancements to IT infrastructure and tools are being developed to support brand partners in growing their businesses [45][46][48]
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
ZACKS· 2025-07-22 22:21
Group 1: Earnings Performance - USANA Health Sciences reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.54 per share, and up from $0.54 per share a year ago, representing an earnings surprise of +37.04% [1] - The company posted revenues of $235.85 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.73%, compared to year-ago revenues of $212.87 million [2] - Over the last four quarters, USANA has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - USANA Health shares have declined approximately 15.6% since the beginning of the year, while the S&P 500 has gained 7.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.65 on revenues of $225.82 million, and for the current fiscal year, it is $2.61 on revenues of $946.98 million [7] Group 3: Industry Context - The Medical - Drugs industry, to which USANA belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact USANA's stock performance [5] - Another company in the same industry, Aquestive Therapeutics, is expected to report a quarterly loss of $0.18 per share, reflecting a significant year-over-year decline [9]
USANA Health Sciences(USNA) - 2025 Q2 - Quarterly Results
2025-07-22 20:06
[Q2 2025 Financial Highlights](index=1&type=section&id=Key%20Financial%20Results) USANA's Q2 2025 saw consolidated net sales rise 11% to $236 million, with GAAP net earnings declining but adjusted diluted EPS growing 36% Q2 2025 Financial Performance vs. Q2 2024 | Metric | Q2 2025 | YoY Change | Sequential Change | | :--- | :--- | :--- | :--- | | **Net Sales** | $236 million | +11% | -5% | | **Net Earnings** | $9.7 million | -7% | +3% | | **Diluted EPS** | $0.52 | -4% | +6% | | **Adjusted Diluted EPS** | $0.74 | +36% | +1% | | **Adjusted EBITDA** | $30.5 million | +13% | +2% | - Direct selling Active Customers decreased to **418,000** from **468,000** in the prior year, while the newly acquired Hiya business reported **200,400** Active Monthly Subscribers[4](index=4&type=chunk) - Management confirmed that the business performed in line with expectations and maintained the fiscal 2025 outlook[5](index=5&type=chunk) [Management Commentary and Strategy](index=2&type=section&id=Management%20Commentary) Management is implementing a new commercial strategy for direct sales, rebranding members as 'Brand Partners,' while the Hiya DTC business shows strong growth and a new Disney partnership - The company is rolling out a new commercial strategy for its direct sales business, which involves enhanced sales incentives, a simplified model, improved business support, and refreshed brand messaging[6](index=6&type=chunk) - The terminology for members of the direct sales business has been changed to "**Brand Partner**"[6](index=6&type=chunk) - The Hiya business demonstrated strong top-line growth and improved profitability, launching a new partnership with Disney featuring special edition Lion King and Princesses branded multivitamins[7](index=7&type=chunk) [Business Segment & Regional Performance](index=2&type=section&id=Business%20Segment%20%26%20Regional%20Performance) Direct selling sales declined across all regions, totaling $199.1 million, while the Hiya direct-to-consumer segment generated $34 million in net sales [Direct Selling Regional Results](index=2&type=section&id=Direct%20Selling%20Regional%20Results) Q2 2025 Direct Selling Performance by Region (YoY) | Region | Net Sales (Millions) | YoY Change | Active Customers (Thousands) | YoY Change | | :--- | :--- | :--- | :--- | :--- | | **Asia Pacific** | $163 | -4% | 336 | -9% | | Greater China | $113 | -2% | 231 | -8% | | North Asia | $17 | -13% | 37 | -12% | | Southeast Asia Pacific | $33 | -7% | 68 | -12% | | **Americas and Europe** | $39 | -8% | 82 | -17% | [Hiya Direct-to-Consumer Results](index=3&type=section&id=Hiya%20Direct%20to%20Consumer%20Results) Q2 2025 Hiya Performance | Metric | Value | | :--- | :--- | | **Net Sales** | $34 million | | **Active Monthly Subscribers** | 200,400 | [Financial Position and Capital Allocation](index=3&type=section&id=Balance%20Sheet%20and%20Share%20Repurchase%20Activity) USANA maintained a strong balance sheet with $151 million cash and no debt, generating $13 million in operating cash flow and repurchasing $15 million in shares - Generated **$13 million** in operating cash flow during the second quarter[11](index=11&type=chunk) - Ended the quarter with **$151 million** in cash and cash equivalents and **zero debt**[11](index=11&type=chunk) - Repurchased **528,000 shares** for **$15 million**, with approximately **$34 million** remaining under the current share repurchase authorization[11](index=11&type=chunk) [Fiscal Year 2025 Outlook](index=3&type=section&id=Fiscal%20Year%202025%20Outlook) USANA reiterated its FY2025 outlook, projecting consolidated net sales of $920 million to $1.0 billion, driven by Hiya growth despite direct sales promotional costs Fiscal Year 2025 Guidance | Metric | Range | | :--- | :--- | | **Consolidated Net Sales** | $920 million to $1.0 billion | | **Net Earnings** | $29 million to $41 million | | **Diluted EPS** | $1.50 to $2.20 | | **Adjusted Diluted EPS** | $2.35 to $3.00 | | **Adjusted EBITDA** | $107 million to $123 million | - The outlook anticipates net sales from the direct selling business of **$775 million to $840 million**[15](index=15&type=chunk) - Net sales from Hiya are projected to be **$145 million to $160 million**, reflecting significant year-over-year growth of **29% to 42%**[15](index=15&type=chunk) - The outlook includes an effective tax rate of **44.0% to 45.0%** and accounts for fiscal 2025 being a 53-week year[15](index=15&type=chunk) [Non-GAAP Financial Measures & Reconciliations](index=5&type=section&id=Non-GAAP%20Financial%20Measures) USANA provides non-GAAP measures like Adjusted EBITDA and Adjusted Diluted EPS, excluding acquisition-related costs, to offer a clearer view of core operational performance - **Adjusted Diluted EPS** is a non-GAAP measure that excludes acquisition-related costs like transaction costs, integration expenses, and amortization of intangible assets[16](index=16&type=chunk)[20](index=20&type=chunk) - **Adjusted EBITDA** is a non-GAAP measure that adjusts net earnings for interest, taxes, depreciation, amortization, non-cash share-based compensation, and transaction/integration costs for the Hiya acquisition[17](index=17&type=chunk)[19](index=19&type=chunk) Q2 2025 GAAP to Non-GAAP Reconciliation Highlights | Metric | GAAP | Adjustments | Non-GAAP (Adjusted) | | :--- | :--- | :--- | :--- | | **Net Earnings (attributable to USANA)** | $9.7 million | +$4.1 million | $13.7 million | | **Diluted EPS** | $0.52 | +$0.22 | $0.74 | [Financial Statements](index=12&type=section&id=Financial%20Statements) The condensed consolidated financial statements detail performance, showing gross profit at $185.7 million, earnings from operations at $16.7 million, total assets at $734.5 million, and total liabilities at $148.9 million Condensed Consolidated Statement of Operations (Q2 2025 vs Q2 2024, in thousands) | Line Item | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Net sales** | $235,848 | $212,869 | | **Gross profit** | $185,664 | $172,536 | | **Earnings from operations** | $16,718 | $17,840 | | **Net earnings attributable to USANA** | $9,655 | $10,432 | Condensed Consolidated Balance Sheet (As of June 28, 2025, in thousands) | Line Item | Amount | | :--- | :--- | | **Cash and cash equivalents** | $151,338 | | **Total current assets** | $261,866 | | **Total assets** | $734,526 | | **Total current liabilities** | $121,625 | | **Total stockholders' equity** | $531,060 | - Total Active Brand Partners decreased from **193,000** in Q2 2024 to **172,000** in Q2 2025, while Total Active Preferred Customers decreased from **275,000** to **246,000** over the same period[37](index=37&type=chunk)[38](index=38&type=chunk)
USANA Health Sciences: Premium Formulation, Discounted Valuation
Seeking Alpha· 2025-07-04 15:42
Core Insights - The article emphasizes a focused investment strategy in the micro-cap segment, utilizing technical analysis and the CAN SLIM methodology to identify high-growth companies often overlooked by mainstream analysts [1] - The approach seeks emerging businesses with strong financial momentum, rapid earnings growth, and signs of institutional interest, which are indicators of potential stock price increases [1] - The research process integrates both fundamental and technical perspectives, focusing on indicators like relative strength, unusual trading volume, and earnings acceleration to identify stocks poised for significant breakouts [1] Investment Strategy - The investment strategy combines technical analysis with the CAN SLIM methodology, which is designed to uncover high-growth companies [1] - The focus is on identifying stocks with strong financial momentum and rapid earnings growth, as well as institutional interest [1] - The goal is to spot opportunities early, before broader market recognition drives prices higher [1] Research Process - The research process includes both fundamental and technical analysis, paying close attention to key indicators [1] - Indicators such as relative strength, unusual trading volume, and earnings acceleration are critical in identifying potential breakout stocks [1] - The multi-market background in Forex trading enhances the ability to interpret price action and market sentiment [1] Community Engagement - Writing on Seeking Alpha is an integral part of the investment process, allowing for validation of ideas and documentation of research [1] - The articles aim to uncover under-the-radar growth stocks with compelling fundamentals and favorable technical setups [1] - The ultimate goal is to provide insightful and actionable content to help others navigate the market with greater confidence [1]
USANA Executive Chairman Kevin Guest Invites All to Discover Freedom in July
Prnewswire· 2025-07-02 11:37
Company Overview - USANA Health Sciences is a global leader in health and wellness products, focusing on social wellness as a key component of its business strategy since its founding in 1992 [8] - The company operates in 25 countries, emphasizing clear communication to build trust with customers and distributors [8] Leadership Insights - Kevin Guest, the Executive Chairman of USANA, emphasizes the importance of personal freedom and self-care, encouraging individuals to take control of their independence [2][6] - Guest's book, "All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony," outlines principles for achieving personal empowerment and harmony [2][5] Principles for Personal Empowerment - Guest identifies five key actions to celebrate personal freedom: releasing limiting beliefs, overcoming self-doubt, leaving toxic relationships, defeating loneliness, and prioritizing self-care [7] - The essence of freedom is described as inspiring joy, cultivating confidence, and transforming lives [6] Social Responsibility - Proceeds from Guest's book are dedicated to feeding hungry children, with each purchase providing 40 meals, highlighting the company's commitment to social responsibility [6]
USANA Health (USNA) Upgraded to Buy: Here's What You Should Know
ZACKS· 2025-06-17 17:00
Core Viewpoint - USANA Health Sciences (USNA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The correlation between earnings estimate revisions and near-term stock price movements makes the Zacks rating system valuable for investors, as it provides a clearer picture than subjective Wall Street analyst ratings [3][7]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock prices, as they adjust their valuations based on these estimates, leading to significant stock transactions that affect price movements [5]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade for USANA Health suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [6]. Earnings Estimate Revisions for USANA Health - For the fiscal year ending December 2025, USANA Health is expected to earn $2.61 per share, with no year-over-year change, but the Zacks Consensus Estimate has increased by 1.8% over the past three months [9]. Zacks Rank System Performance - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of USANA Health to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].
5 Low Price-to-Book Value Stocks That You Can Buy in June
ZACKS· 2025-06-17 14:05
Core Insights - Value investing provides an opportunity to acquire overlooked stocks that are trading at low multiples, particularly using the price-to-book (P/B) ratio as a metric for identifying potential bargains with high-growth prospects [1][2] Understanding P/B Ratio - The P/B ratio is calculated as market capitalization divided by book value of equity, helping to identify low-priced stocks with high growth potential [2] - A P/B ratio of less than one indicates that a stock is undervalued, while a ratio greater than one suggests it may be overvalued [5][6] - The P/B ratio is particularly relevant for industries with tangible assets, such as finance and manufacturing, but may be misleading for companies with high R&D expenditures or significant debt [8] Screening Parameters - Stocks were screened based on several criteria, including a P/B ratio less than the industry median, a P/S ratio lower than the industry average, and a PEG ratio of less than 1, indicating undervaluation relative to growth prospects [11][12][13] - Additional criteria included a minimum current price of $5, an average 20-day trading volume of at least 100,000, and a Zacks Rank of 1 or 2, which indicates strong buy potential [14] Selected Stocks - Five stocks identified with low P/B ratios and strong projected EPS growth include: - **USANA Health Sciences (USNA)**: Projected 3-5 year EPS growth rate of 12.0%, Zacks Rank 2, Value Score A [15] - **CVS Health (CVS)**: Projected 3-5 year EPS growth rate of 11.4%, Zacks Rank 2, Value Score A [16] - **Pfizer (PFE)**: Projected 3-5 year EPS growth rate of 9.0%, Zacks Rank 2, Value Score A [17] - **StoneCo (STNE)**: Highest projected 3-5 year EPS growth rate at 26.3%, Zacks Rank 1, Value Score B [10][18] - **Paysafe Limited (PSFE)**: Projected 3-5 year EPS growth rate of 17.9%, Zacks Rank 2, Value Score A [19]
USANA CEO Elected to Board of Direct Selling Association
Prnewswire· 2025-06-17 11:17
Group 1 - USANA President and CEO Jim Brown has been elected to the Board of Directors of the Direct Selling Association (DSA) for a three-year term [1] - Jim Brown has over 25 years of leadership experience, with 19 years at USANA in various roles [1] - The DSA has been a national trade association for direct selling companies for over a century, generating $36.7 billion in retail sales in 2023 [2] Group 2 - In 2023, 6.1 million entrepreneurs in the U.S. engaged in direct selling, providing a personalized buying experience for customers [2] - DSA CEO David Grimaldi expressed confidence in Jim Brown's impact on the board, highlighting his significant experience in the industry [3] - USANA has been recognized for its quality nutritional and lifestyle products for over 30 years [4]
USANA Executive Chairman Kevin Guest Celebrates National Outdoors Month with a Call to Reconnect with Nature
Prnewswire· 2025-06-02 11:03
Company Overview - USANA Health Sciences is a global leader in health and wellness products, emphasizing the importance of social wellness in building a successful business [8] - Since its founding in 1992, USANA has focused on clear communication to build trust with customers and distributors across 25 countries [8] Leadership Insights - Kevin Guest, Executive Chairman of USANA, encourages individuals and families to celebrate National Outdoors Month by engaging with nature, drawing from his personal experiences growing up in Montana [1][2] - Guest's book, "All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony," highlights the transformative power of nature and its role in achieving physical, mental, and emotional well-being [2][6] Benefits of Nature - Physical Health Improvements: Engaging in outdoor activities enhances physical fitness, cardiovascular health, and energy levels [3] - Mental Well-Being Enhancement: Nature has been shown to alleviate anxiety and improve mood, acting as a healer that restores balance [4] - Stress Reduction: Time spent in green spaces lowers cortisol levels, aiding in stress management [4] - Creativity Boosts: The outdoors fosters imagination and innovation, providing a tranquil environment for inspiration [5] - Social Bonding Opportunities: Nature serves as a setting for strengthening relationships and building meaningful connections [5] Corporate Social Responsibility - Proceeds from Guest's book go towards feeding hungry children, with each purchase providing 40 meals [7]